<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 27 May 2021 11:16:22 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>传奇生物BCMA CAR-T上市申请获FDA优先审评</title><link>https://mp.weixin.qq.com/s/SFoFU9P4dJewcj6h1cvNyg</link><description></description><content:encoded><![CDATA[传奇生物BCMA CAR-T上市申请获FDA优先审评]]></content:encoded><pubDate>Thu, 27 May 2021 10:57:26 +0800</pubDate></item><item><title>阿斯利康中国与博安生物达成重磅战略合作，助力本土抗肿瘤生物药扩面县域市场</title><link>https://mp.weixin.qq.com/s/4H7APUn6ifpQ7am849wjlQ</link><description></description><content:encoded><![CDATA[阿斯利康中国与博安生物达成重磅战略合作，助力本土抗肿瘤生物药扩面县域市场]]></content:encoded><pubDate>Thu, 27 May 2021 10:57:26 +0800</pubDate></item><item><title>璎黎药业/恒瑞选择性PI3Kδ抑制剂上市申请拟优先审评</title><link>https://mp.weixin.qq.com/s/L8gTY7KMJIt5HgFB1PCPrw</link><description></description><content:encoded><![CDATA[璎黎药业/恒瑞选择性PI3Kδ抑制剂上市申请拟优先审评]]></content:encoded><pubDate>Thu, 27 May 2021 10:57:26 +0800</pubDate></item><item><title>苏建华博士出任岸迈生物CSO</title><link>https://mp.weixin.qq.com/s/0Lq8MJeMLn-QDp1ou4lfHw</link><description></description><content:encoded><![CDATA[苏建华博士出任岸迈生物CSO]]></content:encoded><pubDate>Thu, 27 May 2021 10:57:26 +0800</pubDate></item><item><title>研发人才向本土Biotech汇聚，下一个趋势是什么？</title><link>https://mp.weixin.qq.com/s/8ZltyzS4DUdk0ayV2HDI9A</link><description></description><content:encoded><![CDATA[研发人才向本土Biotech汇聚，下一个趋势是什么？]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>进军生物药领域！南京诺唯赞IPO过会，将上科创板</title><link>https://mp.weixin.qq.com/s/fPpwSLCVGKU2vpbC52741g</link><description></description><content:encoded><![CDATA[进军生物药领域！南京诺唯赞IPO过会，将上科创板]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>重磅！中国生物医药五大榜单即将揭晓</title><link>https://mp.weixin.qq.com/s/h9N21McB5B3neGNDmJTWeA</link><description></description><content:encoded><![CDATA[重磅！中国生物医药五大榜单即将揭晓]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>新型抗生素中国III期桥接试验成功！Nabriva股价大涨40%</title><link>https://mp.weixin.qq.com/s/MpNkVWQDJ4Wbdk_cg-pCWQ</link><description></description><content:encoded><![CDATA[新型抗生素中国III期桥接试验成功！Nabriva股价大涨40%]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>直播预告 | 各家药品专利期限补偿谁更赚？专利法第四次修改对国内上市药品的影响</title><link>https://mp.weixin.qq.com/s/XlzgqiiL2eLYgausyXqbuA</link><description></description><content:encoded><![CDATA[直播预告 | 各家药品专利期限补偿谁更赚？专利法第四次修改对国内上市药品的影响]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>拜耳“不限癌种”疗法上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/XHtcj-XOJ4F-2yfpNFzUlw</link><description></description><content:encoded><![CDATA[拜耳“不限癌种”疗法上市申请拟纳入优先审评]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>石药集团CDK9抑制剂、Claudin 18.2分别在中国、美国获批临床</title><link>https://mp.weixin.qq.com/s/ThP2aaKxM2dyO-DDvzib6A</link><description></description><content:encoded><![CDATA[石药集团CDK9抑制剂、Claudin 18.2分别在中国、美国获批临床]]></content:encoded><pubDate>Wed, 26 May 2021 17:53:45 +0800</pubDate></item><item><title>勃林格殷格翰精神分裂症新药获FDA突破性疗法认定</title><link>https://mp.weixin.qq.com/s/6z-n2jVKGpOPnzSDb5F9Vg</link><description></description><content:encoded><![CDATA[勃林格殷格翰精神分裂症新药获FDA突破性疗法认定]]></content:encoded><pubDate>Tue, 25 May 2021 18:16:13 +0800</pubDate></item><item><title>NASH 治疗药物IIb期研究失败，股价暴跌40%</title><link>https://mp.weixin.qq.com/s/AkWno8mntffpA6tYcIDRxw</link><description></description><content:encoded><![CDATA[NASH 治疗药物IIb期研究失败，股价暴跌40%]]></content:encoded><pubDate>Tue, 25 May 2021 18:16:13 +0800</pubDate></item><item><title>KRAS突变卵巢癌患者ORR达70%！RAF/MEK+FAK组合疗法获FDA突破性疗法认定</title><link>https://mp.weixin.qq.com/s/sy1CiMAZmc_Oo77OtlDViQ</link><description></description><content:encoded><![CDATA[KRAS突变卵巢癌患者ORR达70%！RAF/MEK+FAK组合疗法获FDA突破性疗法认定]]></content:encoded><pubDate>Tue, 25 May 2021 18:16:13 +0800</pubDate></item><item><title>凭I/II期数据申报上市！武田EGFR Exon20靶向新药拟优先审评</title><link>https://mp.weixin.qq.com/s/zh3QdRWBq796tMvsh1DCHQ</link><description></description><content:encoded><![CDATA[凭I/II期数据申报上市！武田EGFR Exon20靶向新药拟优先审评]]></content:encoded><pubDate>Tue, 25 May 2021 18:16:13 +0800</pubDate></item><item><title>倒计时一周！红杉中国智能医疗基因组学孵化器火热开启，这6类公司请注意！</title><link>https://mp.weixin.qq.com/s/A4Sj0fO5cuI66DB5BBLKSw</link><description></description><content:encoded><![CDATA[倒计时一周！红杉中国智能医疗基因组学孵化器火热开启，这6类公司请注意！]]></content:encoded><pubDate>Mon, 24 May 2021 16:00:27 +0800</pubDate></item><item><title>绿叶制药利斯的明多日透皮贴剂获欧盟多国上市许可资格</title><link>https://mp.weixin.qq.com/s/Fdvenlmoo9g2HHTOcHPK3A</link><description></description><content:encoded><![CDATA[绿叶制药利斯的明多日透皮贴剂获欧盟多国上市许可资格]]></content:encoded><pubDate>Mon, 24 May 2021 16:00:27 +0800</pubDate></item><item><title>百济神州first-in-class HPK1抑制剂在国内申报临床</title><link>https://mp.weixin.qq.com/s/OpAhkg9M4x1fcOvzfO7ndA</link><description></description><content:encoded><![CDATA[百济神州first-in-class HPK1抑制剂在国内申报临床]]></content:encoded><pubDate>Mon, 24 May 2021 16:00:27 +0800</pubDate></item><item><title>首仿！山东新时代「阿昔替尼片」获批上市</title><link>https://mp.weixin.qq.com/s/OYe1rWPOY-4CBnddMjuG7A</link><description></description><content:encoded><![CDATA[首仿！山东新时代「阿昔替尼片」获批上市]]></content:encoded><pubDate>Mon, 24 May 2021 16:00:27 +0800</pubDate></item><item><title>2021ASCO同频！万春医药公布First In Class普那布林三联免疫方案治疗小细胞肺癌疗效重大突破</title><link>https://mp.weixin.qq.com/s/Qo2AX29SUQhXh96DNgHqoA</link><description></description><content:encoded><![CDATA[2021ASCO同频！万春医药公布First In Class普那布林三联免疫方案治疗小细胞肺癌疗效重大突破]]></content:encoded><pubDate>Mon, 24 May 2021 16:00:27 +0800</pubDate></item></channel></rss>